Home » Topics » BioWorld Science

BioWorld Science
RSS

Topline 12-week data reported from an ongoing phase IIb study of seladelpar in NASH

June 12, 2019

Pharming initiates phase I/II study of Ruconest in patients with pre-eclampsia

June 12, 2019

FDA clears IND for Sleeping Beauty TCR-T-cell therapy trial

June 12, 2019

FDA approves Keytruda for two new indications

June 12, 2019

Eli Lilly initiates phase I study of its bispecific antibody LY-3434172

June 12, 2019

VTS-270 does not show efficacy in phase II/III study in type C Niemann-Pick disease

June 12, 2019

Phase II data presented for NS-0200 in obesity

June 12, 2019

Deciphera adds first-in-class autophagy inhibitor to pipeline

June 12, 2019

Clinical data show potential for improved renal transplant outcomes with CFZ-533

June 12, 2019

Preliminary results from phase I study of MORAb-202 in patients with FRA-positive solid tumors

June 12, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...